Lake Street Initiates Coverage of AbCellera Biologics with Buy Rating
Analyst Daniel Brims at Lake Street has initiated coverage on AbCellera Biologics with a 'Buy' rating and a price target of $19.
Stocks · News reference
Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings report came out
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Analyst Daniel Brims at Lake Street has initiated coverage on AbCellera Biologics with a 'Buy' rating and a price target of $19.
Akanda Corp. has filed to sell 4.82 million common shares, marking a new equity financing action for the company.
Akanda Corp. has terminated its option agreement for a British Columbia property and announced a strategic shift away from cannabis operations.
Radiopharm Theranostics presented interim analysis from its Phase 2b imaging study of RAD101 in suspected recurrent brain metastases at the 31st Society for Neuro-Oncology Annual Meeting.
Piper Sandler analyst Allison Bratzel maintained a bullish rating on AbCellera Biologics Inc. while increasing the price target from $12 to $20.
U.S. stocks fell, led by a 1.1% Nasdaq drop; tech slid while staples rose. Tyson beat estimates, and small-cap movers saw sharp gains and losses.